
Nacuity Pharmaceuticals, backed by FFB, develops breakthrough treatments for retinal diseases.
Nacuity Pharmaceuticals, founded with the mission to develop breakthrough treatments for retinal diseases, focuses primarily on retinitis pigmentosa (RP) and other ophthalmological conditions. The company leverages innovative therapies targeting oxidative stress to halt tissue damage, a key factor in blinding eye diseases and various chronic conditions. Nacuity's product pipeline includes advanced clinical programs addressing RP, cataracts, and cystinosis.
Notable affiliations include significant financial and technical support from the Foundation Fighting Blindness (FFB), which has invested nearly $700 million in research for retinal disease prevention and cures. The accomplished team at Nacuity has driven substantial progress in their clinical programs, positioning the company as a leader in the field of oxidative stress-related treatments. Their work has the potential to significantly impact the lives of individuals suffering from blinding retinal diseases.

EyeCyte
eyecyte.com

Visiox
visioxpharma.com

Nanoscope Therapeutics

Perfuse Therapeutics

Navitor Pharmaceuticals

Vitreoretinal Technologies

Phanes Therapeutics
phanesthera.com

Iacta Pharmaceuticals

OcuCure Therapeutics

MingSight Pharmaceuticals
mingsight.com

Bioxytech Retina
bioxytech.com

Accuitis
accuitis.com

NuvOx Pharma
nuvoxpharma.com

Aurion Biotech
aurionbiotech.com

Neurana Pharmaceuticals
neuranapharma.com
Companies similar to Nacuity Pharmaceuticals include EyeCyte, Visiox, Nanoscope Therapeutics and Perfuse Therapeutics.
Nacuity Pharmaceuticals was founded in 2016.
Nacuity Pharmaceuticals' headquarters is located in Fort Worth, TX, US.
Nacuity Pharmaceuticals' most recent funding round was for $16.5M (USD) in June 2022.
As of Jun 15, 2022, Nacuity Pharmaceuticals has raised a total of $18.5M (USD).
Nacuity Pharmaceuticals has 30 employees as of Feb 5, 2024.